4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioStem Technologies, Inc. (BSEM) operates in the Biotechnology industry and is headquartered in Fort Lauderdale, United States with about 73 employees. Its market capitalization is roughly $66 million. In the fiscal year ended 2024-12-31, BSEM reported $302M in revenue and $32M in net income.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Interactive charts & full statements → Open the BSEM valuation workbench →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $302M | $17M | $7M | $4M |
| Gross Profit | $288M | $15M | $6M | $3M |
| Operating Income (EBIT) | $31M | ($8M) | ($5M) | ($2M) |
| Net Income | $32M | ($8M) | ($7M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | $8M | $10M | $11M | $103M |
| Gross Profit | $5M | $9M | $10M | $99M |
| Operating Income (EBIT) | ($8M) | $1M | $0M | $8M |
| Net Income | ($9M) | $1M | $0M | $16M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets | $140M | $15M | $4M | $3M |
| Total Liabilities | $100M | $16M | $7M | $8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BSEM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms